Financials data is unavailable for this security.
Cash flow in USDView more
In 2023, Enliven Therapeutics Inc increased its cash reserves by 32.55%, or 24.61m. Cash Flow from Financing totalled 234.29m or -- of revenues. In addition the company used 61.27m for operations while cash used for investing totalled 148.41m.
Cash flow per share | -1.92 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 6.46 |
---|---|
Tangible book value per share | 6.46 |
More ▼
Balance sheet in USDView more
Current ratio | 14.39 |
---|---|
Quick ratio | -- |
Total debt/total equity | 0.00 |
---|---|
Total debt/total capital | 0.00 |
More ▼